Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1959 1
1963 1
1965 4
1967 1
1968 1
1969 4
1970 2
1971 6
1972 3
1973 1
1975 20
1976 18
1977 11
1978 14
1979 10
1980 16
1981 12
1982 12
1983 10
1984 22
1985 26
1986 23
1987 22
1988 21
1989 37
1990 27
1991 24
1992 34
1993 22
1994 28
1995 37
1996 24
1997 25
1998 36
1999 33
2000 36
2001 39
2002 34
2003 38
2004 38
2005 36
2006 41
2007 37
2008 35
2009 43
2010 36
2011 39
2012 50
2013 46
2014 60
2015 53
2016 42
2017 45
2018 51
2019 52
2020 38
2021 41
2022 33
2023 46
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

1,513 results

Results by year

Filters applied: . Clear all
Page 1
Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic Review of Observational Studies.
Almirall J, Serra-Prat M, Bolíbar I, Balasso V. Almirall J, et al. Respiration. 2017;94(3):299-311. doi: 10.1159/000479089. Epub 2017 Jul 25. Respiration. 2017. PMID: 28738364 Free article. Review.
We performed a systematic review of the literature to establish conclusive evidence of risk factors for community-acquired pneumonia (CAP). Observational studies (cross-sectional, case-control, and cohort studies) the primary outcome of which was to assess risk factors for …
We performed a systematic review of the literature to establish conclusive evidence of risk factors for community-acquired pneumonia (CAP). …
C FTR variants are associated with chronic bronchitis in smokers.
Saferali A, Qiao D, Kim W, Raraigh K, Levy H, Diaz AA, Cutting GR, Cho MH, Hersh CP; NHLBI TransOmics in Precision Medicine (TOPMed). Saferali A, et al. Eur Respir J. 2022 Aug 10;60(2):2101994. doi: 10.1183/13993003.01994-2021. Print 2022 Aug. Eur Respir J. 2022. PMID: 34996830 Free PMC article.
CONCLUSIONS: Cigarette smokers who carry one deleterious CFTR variant have higher rates of chronic bronchitis, while presence of two CFTR variants may be associated with COPD. These results indicate that genetically mediated reduction in CFTR function contributes to …
CONCLUSIONS: Cigarette smokers who carry one deleterious CFTR variant have higher rates of chronic bronchitis, while presence …
Understanding Early COPD.
Lee BY, Han MK. Lee BY, et al. Respir Care. 2023 Jul;68(7):881-888. doi: 10.4187/respcare.10612. Respir Care. 2023. PMID: 37353336
The concept of GOLD 0 was introduced in the hopes that symptoms would help to identify those at greatest risk for progression. While symptoms are a risk factor, in particular chronic bronchitis, the term was abandoned as the majority of individuals at risk who progr …
The concept of GOLD 0 was introduced in the hopes that symptoms would help to identify those at greatest risk for progression. While symptom …
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.
Martinez FJ, Criner GJ, Gessner C, Jandl M, Scherbovsky F, Shinkai M, Siler TM, Vogelmeier CF, Voves R, Wedzicha JA, Bartels C, Bottoli I, Byiers S, Cardenas P, Eckert JH, Gutzwiller FS, Knorr B, Kothari M, Parlikar R, Tanase AM, Franssen FME. Martinez FJ, et al. Am J Respir Crit Care Med. 2023 Aug 15;208(4):417-427. doi: 10.1164/rccm.202303-0458OC. Am J Respir Crit Care Med. 2023. PMID: 37411039 Free PMC article. Clinical Trial.
After 12 weeks of icenticaftor treatment, no dose-response relationship for change from baseline in trough FEV(1) was observed; however, it was observed for E-RS cough and sputum score. A dose-response relationship was observed after 24 weeks for troug …
After 12 weeks of icenticaftor treatment, no dose-response relationship for change from baseline in trough FEV(1) was observed; howev …
Use of CAPTURE to Identify Individuals Who May or May Not Require Treatment for Chronic Obstructive Pulmonary Disease.
Li Y, Wen F, Ma Q, Chen R, Sun Y, Liu T, Gu C, Hu S, Song J, Compton C, Zheng J, Zhong N, Jones P. Li Y, et al. Am J Respir Crit Care Med. 2023 Aug 15;208(4):435-441. doi: 10.1164/rccm.202303-0504OC. Am J Respir Crit Care Med. 2023. PMID: 37315325
CAPTURE was tested as questions alone and with peak expiratory flow measurement. Sensitivity, specificity, and positive and negative predicted values (PPV and NPV) were calculated for COPD Assessment Test (CAT) scores 10 versus <10, modified Medical Research Coun …
CAPTURE was tested as questions alone and with peak expiratory flow measurement. Sensitivity, specificity, and positive and negative pred …
Assessing the genetic relationship between gastroesophageal reflux disease and chronic respiratory diseases: a mendelian randomization study.
Cheng X, Shi J, Zhang D, Li C, Xu H, He J, Liang W. Cheng X, et al. BMC Pulm Med. 2023 Jul 4;23(1):243. doi: 10.1186/s12890-023-02502-8. BMC Pulm Med. 2023. PMID: 37403021 Free PMC article.

Various sensitivity analyses were also performed to verify the robustness of the findings. RESULTS: Our study demonstrated that genetically predicted GERD was causally associated with an increased risk of asthma (OR 1.39, 95%CI 1.25-1.56, P < 0.001), idiopathic pulmonar

…
Various sensitivity analyses were also performed to verify the robustness of the findings. RESULTS: Our study demonstrated that genetically …
Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis.
Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG. Cazzola M, et al. Pulm Pharmacol Ther. 2018 Feb;48:185-194. doi: 10.1016/j.pupt.2017.11.009. Epub 2017 Dec 9. Pulm Pharmacol Ther. 2018. PMID: 29233650 Review.
Our findings included data from ten studies involving 1278 patients and show that erdosteine is able to improve the clinical score of patients with chronic bronchitis and COPD, and also reduces the overall risk of chronic bronchitis/COPD exacerb …
Our findings included data from ten studies involving 1278 patients and show that erdosteine is able to improve the clinical score of …
Respiratory symptoms and chronic bronchitis in people with and without HIV infection.
Sabin CA, Kunisaki KM, Bagkeris E, Post FA, Sachikonye M, Boffito M, Anderson J, Mallon P, Williams I, Vera JH, Johnson M, Babalis D, Winston A. Sabin CA, et al. HIV Med. 2021 Jan;22(1):11-21. doi: 10.1111/hiv.12955. Epub 2020 Sep 6. HIV Med. 2021. PMID: 32892488 Free article.
OBJECTIVES: High rates of respiratory symptoms and chronic bronchitis (CB) are reported in people with HIV infection (PWH). ...Respiratory symptoms and CB were both associated with greater depressive symptom scores and poorer quality of life. No strong associ …
OBJECTIVES: High rates of respiratory symptoms and chronic bronchitis (CB) are reported in people with HIV infection (PWH). .. …
Serum IL-8 as a Determinant of Response to Phosphodiesterase-4 Inhibition in Chronic Obstructive Pulmonary Disease.
Govoni M, Bassi M, Santoro D, Donegan S, Singh D. Govoni M, et al. Am J Respir Crit Care Med. 2023 Sep 1;208(5):559-569. doi: 10.1164/rccm.202301-0071OC. Am J Respir Crit Care Med. 2023. PMID: 37192443
Rationale: Phosphodiesterase-4 (PDE4) inhibitors have demonstrated increased efficacy in patients with chronic obstructive pulmonary disease who had chronic bronchitis or higher blood eosinophil counts. Further characterization of patients who are most likely to ben …
Rationale: Phosphodiesterase-4 (PDE4) inhibitors have demonstrated increased efficacy in patients with chronic obstructive pulmonary disease …
Associations of dietary fiber intake with chronic inflammatory airway diseases and mortality in adults: a population-based study.
Lin S, Zhu N, Zhang S. Lin S, et al. Front Public Health. 2023 May 26;11:1167167. doi: 10.3389/fpubh.2023.1167167. eCollection 2023. Front Public Health. 2023. PMID: 37304115 Free PMC article.
The participants had a mean age of 50.70 17.4 years and was 47.2% male. The prevalence of CIAD, asthma, chronic bronchitis, and COPD were 20.1, 15.2, 6.3, and 4.2%, respectively. ...After adjusting for all confounding factors, linear and negative associations were …
The participants had a mean age of 50.70 17.4 years and was 47.2% male. The prevalence of CIAD, asthma, chronic bronchitis, an …
1,513 results